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by the enzyme sterol-C-24-methyltransferase. A second ac-
tion of abafungin seems to be a direct effect on the fungal 
cell membrane.  Conclusion: The observed characteristics of 
abafungin indicate that abafungin might be a promising an-
tifungal agent defining a new class of antimycotics. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 In the past decades, fungal infections have increased, 
especially in immuno-compromised patients  [1–4] . The 
currently used antifungal drugs belong to ten different 
major groups of substances  [5] . These are the allylamines, 
benzofurans, echinocandins, hydroxypyridones, imid-
azoles, morpholines, polyenes, pyrimidines, thiocarba-
mates and triazoles  [6–11] . The target of many of these 
antifungal drugs is ergosterol biosynthesis. Ergosterol is 
one of the key components of the fungal cell membrane. 
As the main sterol of yeasts and other fungi, it is neces-
sary for the growth of cells and normal membrane func-
tion. It serves as a bioregulator of membrane fluidity, 
asymmetry and membrane integrity and contributes to 
the proper function of membrane-bound enzymes  [12] . 
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 Abstract 
 Background:  In  contrast to the increasing numbers of 
agents for the treatment of invasive fungal infections, dis-
coveries of new antifungal agents with therapeutic value in 
dermatomycoses are reported only rarely.  Methods: Aba-
fungin (chemical abstracts service registry No. 129639-79/8) 
is the first member of a novel class of synthetic antifungal 
compounds, the arylguanidines. It was first synthesized at 
Bayer AG, Leverkusen, Germany, and its antifungal action 
was discovered during the screening of H 2 -receptor antago-
nists based on the structure of famotidine. To obtain insight 
into its mode of action and antifungal activity, various tests 
were carried out with different fungal pathogens  in vitro.  Re-
sults: Abafungin was found to have potent antifungal activ-
ity. Furthermore, mode-of-action studies suggested that 
abafungin exerts its antifungal activity regardless of wheth-
er the pathogens are growing or in a resting state. One target 
of abafungin was found to be the inhibition of transmethyl-
ation at the C-24 position of the sterol side chain, catalyzed 
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Over the past 20 years, interference with the ergosterol 
biosynthesis pathway of fungi has been a major aim of 
antifungal drug research and development. Other targets 
are directly related to the cell membrane, the synthesis of 
amino acids or the cell wall.
 Terbinafine is the major drug from the class of the al-
lylamines. It exhibits a primarily fungicidal mode of ac-
tion. It attacks a broad range of dermatophytes and molds 
but shows lower activity against yeasts  [13] . Terbinafine 
acts on fungal ergosterol biosynthesis by specific and se-
lective inhibition of fungal squalene epoxidase. This leads 
to intracellular accumulation of squalene and prevents 
the synthesis of lanosterol. Its affinity to cytochrome P 450 
is lower than that of azoles. Consequently, terbinafine 
shows lower interaction in co-medication in comparison 
to the azoles.
 The benzofuran griseofulvin is one of the oldest sys-
temically administered antifungal drugs and has been 
used since 1959. Griseofulvin is synthesized by  Penicilli-
um griseofulvum and other  Penicillium  species. Its activ-
ity is limited to dermatophytes. It interacts with microtu-
buli and inhibits fungal cell mitosis. In hyphae of derma-
tophytes, griseofulvin causes the characteristic ‘curling 
effect’. Even using ultramicrosize griseofulvin, which is 
better absorbed, cure rates for toenail onychomycoses are 
 ! 40% despite treatment over 1 year or longer  [14] .
 Caspofungin influences the fungal cell wall by inter-
ference with the synthesis of   -(1,3)- D -glucan  [6, 15] . It 
acts fungicidally on yeasts and fungistatically on  Asper-
gillus  spp.
 The azoles are antifungal compounds with five-mem-
bered rings, which contain either two (imidazoles) or 
three (triazoles) nitrogen atoms. Major imidazoles are 
clotrimazole, miconazole and ketoconazole. Major tri-
azoles are itraconazole, fluconazole and voriconazole. 
The main target of azoles is the fungal cell membrane. 
Inhibition of the cytochrome P 450 3A-dependent lano-
sterol 14-  -demethylase leads to accumulation of 14-  -
methylsterol and depletion of ergosterol  [16] . Addition-
ally, azoles can inhibit some enzymes of the fungal respi-
ratory chain  [17, 18] .
 Ciclopirox olamine and piroctone olamine are topical 
antifungals belonging to the class of hydroxypyridones. 
Their mode of action is not well understood  [19] . Previ-
ous studies have reported that these drugs bind irrevers-
ibly to intracellular compounds and act fungicidally by 
interaction with iron metabolism, metabolic activity and 
oxygen accessibility  [20, 21] .
 Amorolfine is the major drug from the class of mor-
pholines. It interacts with at least two enzymes of the 
 ergosterol biosynthetic pathway,   14 -reductase and the 
  7–8 -isomerase, leading to inhibition of ergosterol bio-
synthesis at different levels  [22, 23] .
 Amphotericin B and nystatin, which belong to the 
polyene antimycotics, primarily build complexes with er-
gosterol. This results in disorganization of the fungal cell 
membrane and formation of specific pores composed of 
small aggregates of the polyene drugs. Increased mem-
brane permeability leads to depolarization and loss of 
proteins, nucleotides and other compounds  [24] . Am-
photericin B also binds unspecifically to other sterols, e.g. 
cholesterol, which accounts for much of its toxicity.
 The halogenated pyrimidine 5-flucytosine is an anti-
metabolite of cytosine. It is selectively taken up by a cy-
tosine permease. Intracellularly, it is deaminated to 5-flu-
orouracil (5-FU). 5-FU is phosphorylated and incorpo-
rated into RNA, where it causes miscoding. Additionally, 
5-FU is converted to its deoxynucleoside, which inhibits 
thymidylate synthetase and thereby DNA synthesis  [25] . 
Because of a fast generation of resistance it is not used for 
monotherapy.
 Thiocarbamates, such as tolnaftate, as well as the al-
lylamines, work by direct inhibition of microsomal squa-
lene epoxidase in ergosterol biosynthesis, which leads to 
an accumulation of squalene  [26] .
 Unfortunately, resistance to older antifungal drugs has 
gained more and more importance in the past years  [27–
29] . Therefore, new antifungal agents are still needed, in 
particular active compounds which might not cause de-
velopment of resistance very rapidly. However, the devel-
opment of resistance is more probable, if an antifungal 
agent inhibits only one essential function of the pathogen, 
e.g. fungal reproduction or membrane synthesis  [28] . In 
particular, new antifungals targeting several functions of 
the fungus simultaneously are urgently needed.
 We report now on the in vitro data of a new promising 
substance, which will probably be introduced into anti-
fungal therapy in the near future. Abafungin, chemical 
abstracts service (CAS) registry No. 129639-79-8CAS, 
was synthesized at Bayer AG, Leverkusen, Germany, 
quite some time ago. It was detected while Bayer per-
formed screening tests looking for H 2 -receptor antago-
nists, using famotidine as lead structure ( fig. 1 a). Aba-
fungin is a compound belonging to a new class of micro-
biocidal arylguanidines. Its chemical structure differs 
from existing antifungals, including azoles ( fig. 1 b). We 
describe tests with abafungin which were performed in 
the 1990s primarily to study the effects on fungi and to 
understand its potential mode of action. The reason to 
report on these data now is that abafungin-based antimy-
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cotics might reach clinical medicine in the near future. 
Thus, the results of the investigations are considered rel-
evant, although currently preferred approaches were not 
always chosen in terms of methodology.
 Materials and Methods 
 Test Media 
 The sensitivity of resting fungi was determined in physiologi-
cal saline or in demineralized water. The nutrient media yeast 
nitrogen base (YNB; Difco Laboratories, Detroit, Mich., USA), 
Kimmig and Sabouraud dextrose are standard media for fungi. 
Kimmig broth, Sabouraud dextrose, T3 medium and additional 
standard media were all from Difco.
 YMM is a hypotonic minimal medium for yeast-like fungi. 
The composition of YMM is as follows:
Ingredients Concentration, g/l
Glucose 10
(NH4)2SO4 2
KH2PO4 1
MgSO47 H2O 0.3
CaCl2 0.03
L-Asparagine 2
 
 The composition of T3 medium is as follows:
Ingredients Concentration, g/l
Glucose 10
(NH4)2SO4 3
KH2PO4 2
Citric acid 2
K2CO3 2
MgSO4 0.7
NaCl 0.5
Difco yeast extract 2.5
Pyridoxal hydrochloride 0.0001
 For testing of fungi, the pH was adjusted with HCl to 5.0.
 Test Organisms 
 Test organisms comprised strains of fungi of differing species, 
most of them medically important. Representatives of yeast-like 
fungi included in particular Candida albicans . Moreover, derma-
tophytes were included. The test organisms consisted exclusively 
of clinical isolates. The isolates had been kept on agar slants and 
passaged several times before the start of the study. Microbial sus-
pensions were prepared and checked photometrically from fresh-
ly grown cultures in physiological saline.
 Two isolates of  C. albicans  were in particular employed in this 
study, strain TIMM 0144 from the Teikyo University collection 
and  C. albicans H12 from Bayer’s culture collection. Both isolates 
were maintained by periodic transfer on Sabouraud dextrose agar. 
The culture of strain TIMM 0144 was initiated by transfer to pep-
tone yeast extract glucose broth overnight at 37 ° C.  Strain H12 was 
initiated in fresh Sabouraud’s slant cultures overnight at 28 ° C.
 Comparative Determination of Minimum Inhibitory 
Concentrations 
 Comparative determination of minimum inhibitory concen-
trations (MICs) was performed using a broth dilution assay either 
on the 5-ml scale (dermatophytes and molds) or on the microliter 
scale (yeasts) and with the agar (agarose) dilution assay. MICs were 
determined using Kimmig’s and T3 media for dermatophytes, and 
YNB glucose and T3 medium for yeast-like fungi. T3 medium was 
also used for molds. The MIC was defined as 100% inhibition of 
detectable growth after the indicated incubation time. Minimum 
fungicidal concentrations (MFCs) were determined in the first 
step, as described for MICs. After the indicated incubation time, 
diluted and undiluted samples were plated on drug-free agar plates 
and incubated for 14 days before colony-forming units (CFU) per 
milliliter were determined. The MFC was defined as the minimal 
drug concentration which reduced the CFU of the fungal inocu-
lum by two to three orders of magnitude.
 Conductivity Measurement 
 A fresh overnight culture of  C. albicans  (strain H12), grown in 
a slant culture at 28 ° C, was washed three times in distilled water 
and resuspended in distilled water to obtain a density of 6  ! 10 8 
CFU/ml. Abafungin was preincubated for 30 min at 37 ° C in a 
water shaker. The conductivity of a cell suspension was measured 
with a standard electrode KLE 1/T (WTW, Wissenschaftlich-
Technische Werkstätten, Weilheim, Germany) connected to a 
conductivity meter LF91 (WTW) before and after adding the cells 
at a final density of 6  ! 10 5 CFU/ml.
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 Determination of Potassium 
 Freshly grown yeast cells of  C. albicans were adjusted to a den-
sity of 10 8 cells/ml in distilled water and placed on a shaker at 
37 ° C.
 After addition of abafungin, samples were taken at the indi-
cated time points and filtered through a glass fiber filter (GF/C, 
Whatman, Dassel, Germany). Potassium content of the extracel-
lular fluid was determined by colorimetric analysis based on 
flame spectrochemical analysis (model 775; Hitachi, Tokyo, Ja-
pan). The released amounts of K + were expressed as a ratio of the 
total amount which was obtained from control cells boiled for 10 
min in trichloroacetic acid. 
 Adenosine Triphosphate Assay 
 C. albicans cells grown overnight in a slant culture were 
washed with distilled water or saline (physiological saline solu-
tion), resuspended in distilled water or YMM at the final density 
indicated in the experiments before abafungin was added at a fi-
nal concentration of 30 mg/l. Measurements of extracellular ad-
enosine triphosphate (ATP) were performed in a bioluminescent 
assay with Lumit (luciferin and luciferase)  [30] . Light emission 
was determined for 10 s in 100   l culture samples mixed with
100   l of the reagent in a Biocounter M 2500 (Perstorp Analytical; 
Lumac, Landgraaf, The Netherlands). To measure total ATP, 100 
  l samples were mixed with 100   l of NRB (Nucleotide Releasing 
Reagent; Perstorp Analytic) to induce cell lysis. After 10 s, 100   l 
of Lumit were added and light intensity was measured concur-
rently.
 UV Difference Spectroscopic Measurements 
 Difference spectra were recorded as described by Epand et al. 
 [31] . All phospholipids and sterols were purchased from Sigma 
(Sigma-Aldrich, Munich, Germany). Abafungin, phospholipid 
(phosphatidylcholine, phosphatidylethanolamine, phosphatidyl-
inositol, phosphatidylserine and cardiolipin) and sterol (sitoster-
ol, cholesterol and ergosterol) were dissolved in ethanol to obtain 
a final concentration of 10 –4  M ; abafungin and phosphatidylserine 
were also diluted to obtain 5  ! 10 –5  M . The sample cuvette was 
then shaken and allowed to stand for 1 min at 22 ° C. Difference 
spectral measurements were made in matched tandem cuvettes at 
room temperature (22 ° C) with an Uvicon 820 spectrophotometer 
(Kontron, Eching, Germany) at wavelengths ranging from 190 to 
350 nm.
 Measurement of Ergosterol Biosynthesis by Incorporation of 
 14 C-Acetate 
 Cells of strain TIMM 0144 were adjusted to 10 7 cells/ml in the 
YNB broth. The suspension was incubated at 37 ° C on a shaker 
with the indicated concentration of abafungin before addition of 
7.4 kBq/ml  14 C-acetate (NEN Research, Boston, Mass., USA). Test 
samples were taken after 3 h of incubation and saponified at 85 ° C 
for 2 h in a mixture of 15% KOH, 50% ethanol and a small amount 
of pyragol. The lipid fraction was extracted with petroleum ether 
and evaporated to dryness before dissolving in ether. The sterol 
was analyzed by thin-layer chromatography. The operation con-
ditions were as follows: for adsorption, AgNO 3  silica gel plates 
were prepared by addition of 10% silver nitrate to silica gel (60C, 
Merck, Darmstadt, Germany). The plates were developed with n-
hexane/isopropylether/ethyl acetate. Radioactivity was measured 
and calculated using a Bio-image analyzer (BAS 2000; Fuji Film, 
Düsseldorf, Germany). Non-radioactive ergosterol was simulta-
neously developed on AgNO 3 silica gel plates and served as a 
marker. 
 Measurement of Ergosterol Biosynthesis by
Gas Chromatography-Mass Spectroscopy  
 C. albicans  cells (strain TIMM 0144), 10 5 cells/ml in YNB 
broth, were incubated with shaking for 24 h at 37 ° C in the pres-
ence of 1   g/ml of abafungin. Test samples were taken, saponified 
and extracted, dissolved in acetone and analyzed by gas chroma-
tography-mass spectroscopy (QP-1000A; Shimadzu, Kyoto, Ja-
pan). The operation conditions were as follows: glass column: DB-
5; carrier gas: helium, and column temperature: 280  ° C. 
 Measurement of Ergosterol Biosynthesis by Incorporation of
 L -[Methyl- 14 C]Methionine 
 Test samples were incubated with different concentrations of 
abafungin or sinefungin (S-adenosyl- L -methionine analog from 
Bayer), as comparative inhibitor, with 7.4 kBq/ml  L -[Methyl- 14 C] 
 methionine (0.2   Ci/ml, NEN Research) for 3 h at 37 ° C in a shak-
er. The non-saponified lipid fractions were extracted and dis-
solved in diethyl ether. The sterols were analyzed by thin-layer 
chromatography. Silica gel plates (F254, Merck) were developed 
with n-heptane/isopropyl ether/acetate. Radioactivity was mea-
sured and calculated using a Bio-image analyzer (BAS2000, Fuji 
Film).
 Results 
 Antifungal Spectrum and Inhibitory Activity 
 MICs for Fungi 
 Abafungin showed broad activity against pathogenic 
fungi. The inhibitory activities against dermatophytes 
 (Trichophyton  spp. , Microsporum  spp.  and Epidermophy-
ton) were somewhat inferior to those of clotrimazole and 
terbinafine, but comparable to that of amorolfine und su-
perior to the ones of bifonazole. It showed better antifun-
gal activity than all used standard compounds against 
the yeast  Candida and the mold  Aspergillus  ( table 1 ). 
Abafungin reduced the growth rate of  C. albicans  to 30 
and 10% at 0.1 and 1   g/ml, respectively, after a 24-hour 
incubation.
 MFCs for Fungi 
 Abafungin showed broad fungicidal activity against 
various species of pathogenic fungi ( table 2 ). The MFCs 
of abafungin with dermatophytes were slightly inferior to 
those with terbinafine but superior to those with all oth-
er comparator drugs. The fungicidal activity of abafun-
gin against yeast-like fungi and molds was clearly supe-
rior to that of all other used reference drugs. A complete 
inhibition of  C. albicans was observed with 10   g/ml af-
ter a 48-hour incubation.
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 Abafungin exerts its fungicidal activity regardless of 
whether the pathogens in question are growing or in a 
resting state. The non-growing dermatophytes and yeast-
like fungi tested to date were killed with drug concentra-
tions  ! 16 mg/l, and only in rare instances 32 mg/l were 
required. When tested against resting fungi, abafungin 
was superior to all the other comparator drugs used, in-
cluding terbinafine and amorolfine ( table 3 ;  fig. 2 ,  3 ).
 Studies on the time dependence of fungicidal activity 
of abafungin revealed that loss of viability was achieved 
in a concentration- and strain-dependent manner. Yeasts 
were killed between 1 and 48 h, and dermatophytes and 
molds between 1 and 5 days after incubation.
Table 1. Antimicrobial activity of abafungin and comparator drugs against various pathogenic fungi (broth dilution assay) 
Organisms Strains
n
MIC range, g/ml
abafungin bifonazole clotrimazole terbinafine amorolfine
Dermatophytes
Trichophyton mentagrophytes
Trichophyton rubrum
Trichophyton equinum
Trichophyton tonsurans
Trichophyton ajelloi
Trichophyton gallinae
Trichophyton schoenleinii
Trichophyton verrucosum
Trichophyton violaceum
Epidermophyton floccosum
Microsporum canis
Microsporum gypseum
Clinical isolates, not characterized
5
5
2
4
1
1
1
2
1
1
4
2
14
≤0.06–0.5
≤0.06–0.25
0.13–0.5
≤0.06–0.25
≤0.06
1
≤0.06
0.13
0.5
0.25
≤0.06–1
≤0.06–2
≤0.06–2
1 to >64
4–8
1–4
1–2
1
1
1
4
>64
1
1–32
16
1–8
≤0.06–1
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06–1
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06–0.13
≤0.06–0.5
≤0.06
≤0.06–4
0.5
2
0.5
≤0.06
0.5
0.13
0.5–1
≤0.06
≤0.06
Yeast
Candida albicans
Candida glabrata
Candida guilliermondii
Candida krusei
Candida tropicalis
Candida parapsilosis
Malassezia furfur
8
8
5
5
7
3
2
0.5–16
0.5–16
0.5–16
0.5–4
4–8
0.5–8
1
8 to >64
32 to >64
>64
>64
>64
>64
–
2–32
1–32
1 to >64
1–2
2–8
1 to >64
–
16 to >64
8 to >64
64 to >64
64 to >64
64 to >64
64 to >64
–
2 to >64
1 to >64
1 to >64
1–4
64 to >64
1 to >64
–
Molds
Aspergillus fumigatus
Aspergillus niger
Aspergillus amsteloidami
Aspergillus repens
Aspergillus ruber
Aspergillus candidus
Aspergillus chevalieri
Aspergillus ustus
Penicillium commune
3
3
2
2
2
1
1
1
1
0.5–1
1
≤0.06–0.5
1–16
0.5–1
1
4
0.5
0.5
64 to >64
>64
64 to >64
>64
>64
>64
64
>64
>64
1–2
1–4
0.13–1
1–4
1
1
1
1
1
32–64
2–4
2–32
4
>64
16
16
16
16
>64
1–64
8
8 to >64
>64
1
>64
16
8
Others
Scopulariopsis brevicaulis
Geotrichum candidum
Madurella mycetomatis
2
1
1
1
8
0.25
>64
>64
>64
0.5
2
1
8
>64
8
8
64
1
Inoculum size: 104 CFU/ml; culture and culturing conditions: dermatophytes = Kimmig’s liquid culture (28° C, 5 days); yeasts = 
YNB liquid culture (37° C, 3 days); molds, others = T3 liquid culture (28° C, 5 days).
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 Effect of Culture Medium, pH and Inoculum Size on 
Activity 
 With  C. albicans TIMM 0144 growing in YNB, slight-
ly delayed activity was observed using 10 mg/l abafungin 
and immediate loss of viability  ! 1 h after addition of 40 
mg/l.
 If the concentration of free agent is reduced by strong 
binding to additives, higher drug concentrations are re-
quired to reach inhibition. This was not only observed 
with proteins but also with agaropectin. When abafungin 
was tested in a Sabouraud dextrose agar dilution assay, 
significantly higher MICs ( table 4 ) were obtained com-
pared to MICs in liquid culture, in particular against 
yeast isolates ( table 1 ). Agar consists of two polymers, the 
neutral agarose and agaropectin with sulfuric acid cova-
lently linked to about every tenth galactopyranose sub-
Table 2. Fungicidal activity of abafungin and comparator drugs against various pathogenic fungi (broth dilution assay)
Organism Strains
n
MFC range, g/ml
abafungin bifonazole clotrimazole terbinafine amorolfine
Dermatophytes
Trichophyton mentagrophytes
Trichophyton rubrum
Trichophyton equinum
Trichophyton tonsurans
Trichophyton ajelloi
Trichophyton gallinae
Trichophyton schoenleinii
Trichophyton verrucosum
Trichophyton violaceum
Epidermophyton floccosum
Microsporum canis
Microsporum gypseum
Clinical isolates, not characterized
5
5
2
4
1
1
1
2
1
1
4
2
14
≤0.06–0.5
≤0.06–0.25
0.5–2
0.25–0.5
≤0.06
1
≤0.06
0.13
0.5
0.25
≤0.06–1
≤0.06–2
≤0.06–2
32
4–32
16–32
16–32
8
8
8
32
32
16
8 to >64
32
8 to >64
1–8
4–8
1–2
8
1
1
2
8
16
1
1–16
1
1–16
≤0.06
≤0.06–0.13
≤0.06
≤0.06
≤0.06
≤0.06
0.13
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06
≤0.06–0.25
0.13–2
0.13–0.5
0.13
0.13–8
0.5
2
1
0.13
2
0.13
1–8
0.13
0.13–1
Yeast
Candida albicans
Candida glabrata
Candida guilliermondii
Candida krusei
Candida tropicalis
Candida parapsilosis
Malassezia furfur
8
8
5
5
7
3
2
8–16
2–16
4–16
2–8
16
8
1
>64
>64
>64
>64
>64
>64
–
2 to >64
4 to >64
1 to >64
2–8
8 to 64
1 to >64
–
32 to >64
4 to >64
>64
>64
>64
>64
–
4 to >64
4 to >64
>64
4 to >64
64 to >64
>64
–
Molds
Aspergillus fumigatus
Aspergillus niger
Aspergillus amsteloidami
Aspergillus repens
Aspergillus ruber
Aspergillus candidus
Aspergillus chevalieri
Aspergillus ustus
Penicillium commune
3
3
2
2
2
1
1
1
1
4
4
4
4–32
4
4
16
4
4
64 to >64
>64
64 to >64
>64
>64
>64
64
>64
>64
>64
64 to >64
>64
>64
>64
>64
64
>64
>64
>64
2–4
2–32
4
>64
16
16
16
16
>64
>64
>64
>64
>64
>64
>64
>64
>64
Others
Scopulariopsis brevicaulis
Geotrichum candidum
Madurella mycetomatis
2
1
1
4
16
4
>64
>64
>64
>64
>64
>64
8
>64
8
>64
>64
>64
Inoculum size: 104 CFU/ml; culture and culturing conditions: dermatophytes = Kimmig’s liquid culture (28° C, 5 days); yeasts = 
YNB liquid culture (37° C, 3 days); molds, others = T3 liquid culture (28° C, 5 days).
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unit. In an agarose dilution assay, no reduction of drug 
activity was observed ( table 5 ). If different batches of aga-
rose were used with different degrees of sulfuric acid sub-
stitution, the activity of abafungin was strongly depen-
dent upon the amount of sulfuric acid present ( table 6 ).
 The influence of inoculum size and pH on the MFC 
was studied by broth dilution assay. The strong fungi-
cidal activity of abafungin in the chemically defined YNB 
glucose medium at pH 5 was almost independent of the 
inoculum size ( table 7 ). The solubility of the agent in salt-
containing protein-free liquid media is about 1 mg/l at 
neutral pH. It increases to 10 mg/l in acidified solutions 
(pH 5.0).
 Abafungin exerts a fungicidal activity preferably in 
defined minimal media or slightly enriched liquid media 
at a pH range of 4.0–5.5. Almost no activity of abafungin 
against yeasts was observed in complex nutrient-rich me-
dia like Kimmig’s medium at pH 6.0 due to pH and pro-
tein binding of the drug. However, if the pH was adjusted 
to 5.0, the increased solubility was sufficient to allow fun-
gicidal effects ( table 8 ).
 Minor decrease of activity was observed if the pH was 
lowered from 5.0 to 3.0. This indicates that the fungicid-
al activity of abafungin was not significantly dependent 
upon pH within this range.
 Mode of Action Studies 
 Mode of action studies with abafungin started with 
the observation that this agent exerts its antifungal activ-
ity regardless of whether the pathogens in question are 
growing or rather in a resting state. One possible target 
for abafungin could therefore consist of the fungal cell 
Antifungal
agent
MFC range, g/ml
dermatophytes
43 isolates 
in demineralized water
yeast
38 isolates
in saline
molds
20 isolates 
in saline
Abafungin 1–16 4–16 4–32
Amorolfine 1 to >64 (85%) 4 to >64 (63%) >64 (0%)
Bifonazole 8 to >64 (18%) >64 (0%) not done
Clotrimazole 8 to >64 (51%) >64 (74%) 64 to >64 (5%)
Terbinafine 1–32 >64 (0%) not done
Isolates killed at 64 mg/l are given in parentheses. The inoculum was 104 CFU/ml. 
Dermatophytes and molds were incubated at 28° C for 5 days, yeasts for 3 days at 37° C.
Table 3. Fungicidal activity of abafungin 
and comparator drugs against resting 
cells
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+
1 2 4 8
Drug concentration (mg/l)
16 32 64
100
80
60
40
20
St
ra
in
s 
ki
lle
d
 (%
) Clotrimazole
Terbinafine
Abafungin
+
+
+ ++
+ Amorolfine
0
 Fig. 3. Fungicidal activity of different antifungals against 39 clin-
ical isolates of yeasts in physiological saline. MFC (99% reduction 
of 10 4 CFU/ml) was determined after 3 days of incubation at 
37 ° C. 
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Table 4. Antimicrobial activity of abafungin and comparator drugs against various pathogenic fungi (agar di-
lution test)
Organism Strains
n
MFC range, g/ml
abafungin bifonazole clotrimazole
Dermatophytes
Trichophyton mentagrophytes
Trichophyton rubrum
Trichophyton violaceum
Microsporum audoinii
Microsporum canis
Microsporum gypseum
Epidermophyton floccosum
7
2
1
1
4
2
3
0.08–0.63
0.31
0.63
0.63
0.08–1.25
0.63–1.25
≤0.04–0.16
0.16–5
0.63–5
10
10
1.25–10
10
≤0.04
0.08–1.25
0.08–0.63
1.25
0.63
0.08–1.25
0.63
0.16–0.31
Yeast
Candida albicans
Candida albicans var. stellatoidea
Candida tropicalis
Candida kefyr
Candida parapsilosis
Candida krusei
Candida guilliermondii
Candida glabrata
Cryptococcus neoformans
Cryptococcus laurentii
Cryptococcus terreus
Trichosporon cutaneum
Rhodotorula cutanea
Malassezia furfur
Malassezia pachydermatitis
3
1
2
1
1
1
1
2
3
1
1
2
1
8
11
10–80
10
40
10
20
5
5
10–80
20–80
5
0.31
2.5–20
0.63
2.5–40
0.63–10
20–40
40
80
10
40
20
20
5–40
10–20
1.25
0.63
0.31–5
0.31
2.5–20
1.25–10
5–20
2.5
10
2.5
1.25
1.25
2.5
0.63–10
2.5–5
0.16
5
0.16–1.25
0.63
10–80
10–80
Molds
Aspergillus fumigatus
Aspergillus clavatus
Aspergillus flavus
Aspergillus nidulans
Aspergillus niger
Aspergillus terreus
Aspergillus versicolus
Penicillium citrinum
Penicillium commune
Penicillium crustaceum
3
1
1
2
1
2
1
1
1
1
1.25–2.5
20
>80
2.5–5
10
1.25
5
5
10
5
2.5
40
20
2.5
2.5
1.25–2.5
10
2.5
2.5
1.25
2.5
2.5
2.5
0.16–0.63
5
2.5
5
2.5
2.5
1.25
Dematiaceous fungi
Fonsecaea pedrosoi
Fonsecaea compacta
Phialophora verrucosa
Exophiala dermatitidis
Exophiala werneckii
Cladosporium bantianum
Cladosporium mansonii
2
2
2
2
2
2
2
0.63–1.25
1.25
5–10
5–10
5–10
2.5
0.63
≤0.04
0.08–0.16
0.63
0.63–1.25
0.31–1.25
1.25
≤0.04–0.16
0.31–2.5
5
5
5–10
1.25–2.5
10
0.63–1.25
Dimorphic fungi
Sporothix schenckii
Histoplasma capsulatum
Paracoccidioides brasiliensis
Blastomyces dermatitis
Geotrichum candidum
3
2
3
2
1
1.25
0.16–0.31
0.16–1.25
≤0.08–0.16
>80
20
0.31–0.63
≤0.04–5
≤0.04–2.5
80
20
0.08
0.16–0.63
0.08–0.63
10
Inoculum size = 106 CFU/ml. Culture and culturing conditions: dermatophytes/dematiaceous fungi = Sabouraud dextrose 
agar culture (27° C, 7 days); yeast-like fungi (Malassezia) = potato dextrose agar culture (27° C, 5 days); dimorphic fungi = 
 Sabouraud dextrose agar culture (27° C, 10 days).
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membrane. The impairment of the cell membrane func-
tion was tested by direct measurements of conductivity 
increase. Studies were carried out with  C. albicans, and it 
was observed that abafungin, similar to polymers, caused 
a release of ions from cells within 2 min after addition of 
10 mg/l or with higher concentrations. The ion release 
was measured as conductivity increase in the supernatant 
of resting cells ( fig. 4 ). Further studies indicated that, 
within this short period, K + representing monovalent cat-
ions was released into the supernatant ( fig. 5 ). Simultane-
ously, ATP leakage and ATP degradation were observed 
in resting cells. While total (intra- and extracellular) ATP 
decreased until about 7 min after drug addition, during 
the same time period extracellular ATP reached about 
60% of its maximum level ( fig. 6 ). Already after 5 min, 
the number of CFU in the culture was reduced to  ! 0.1% 
( fig. 6 ). In growing cells immediately after drug addition, 
a short but significant increase in ATP synthesis was ob-
served above control level followed by ATP degradation. 
Compared to resting cells, ATP leakage was reduced. The 
loss of viability occurred later in growing cells  [32] 
( fig. 7 ).
 The observed effects of abafungin indicate that this 
new agent has probably at least two modes of action in 
yeast cells. At a low concentration (10 –7  M ), a specific in-
hibition of ergosterol biosynthesis was found. At higher 
Table 5. Fungicidal activity of abafungin and comparator drugs 
against  Candida spp. (agarose dilution test)
Organism Strains
n
MFC-range, g/ml
abafungin
Yeasts
Candida albicans 10 0.5–8
Candida tropicalis 10 2–16
Candida krusei 5 0.5–4
Candida glabrata 10 1–4
Inoculum size = 106 cells/ml. Culture and culturing condi-
tions: yeasts = Sabouraud dextrose agarose (37° C, 4 days); subcul-
ture on drug-free agar plates (37° C, 14 days).
Table 6. Effect of agar/agarose on the susceptibility of clinical iso-
lates of  C. albicans (n = 25) to abafungin and bifonazole
Agar/agarose Sulfated
ash1
Geometric mean MIC, g/ml
abafungin bifonazole
Agarose A 0.1 1.78 7.60
Agarose B 0.35 11.1 6.80
Agarose C 1.0 >80 5.80
Agar 2–6 >80 5.36
Medium = casitone 0.9%, glucose 2%, yeast extract 1%, 
KH2PO4 0.1%, Na2HPO4 0.1%, sodium citrate 1%; medium pH = 
6.4; test condition = 27° C, 4 days; inoculum size = 106 cells/ml.
1 Residue on combustion.
Table 7. Dependence of the fungicidal activity of abafungin on the 
inoculum size of  C. albicans H12
Inoculum, CFU/ml MFC, g/ml
102 4
103 4–8
104 8
105 8–16
106 16–32
MFC (99.9% reduction in CFU) after 2 days of incubation at 
37° C in yeast nitrogen. Base with 1% glucose.
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*
 Fig. 4. Increase in conductivity by abafun-
gin. Inoculum size of  C. albicans  H12: 10 8 
CFU/ml in distilled water. 
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concentrations (10 –4  M ), the drug caused lethal direct 
membrane damage. Irrespective of the potential physio-
logical relevance of these concentrations, we felt tempted 
to address the question of whether these membrane ef-
fects were induced by a specific interaction with mem-
brane components. We recorded difference spectra with 
various lipids and phospholipids. No interaction of aba-
fungin was seen with the phospholipids, phosphatidyl-
choline, phosphatidylethanolamine and cardiolipin, very 
weak signals with phosphatidylinositol and strong inter-
action with phosphatidylserine ( fig. 8 ). Using similar ex-
periments with cholesterol, ergosterol and sitosterol, 
spectra did not differ.
 Effect on Ergosterol Biosynthesis 
 During initial investigations of the fungicidal mode of 
action of abafungin against phythopathogenic fungi, an 
accumulation of lanosterol was found by gas chromatog-
raphy-mass spectroscopy analysis of the sterols [Berg, 
unpubl. results]. This is indicative of an inhibition of the 
enzyme sterol-C-24 methyltransferase which transfers a 
methyl group to the C-24 position of the side chain of 
lanosterol. Sterol C-24 methylation is a cytochrome P 450 -
independent process, requiring S-adenosyl- L -methio-
nine as the methyl donor. Therefore, we examined the 
incorporation rate of  L -[methyl- 14 C] - methio nine into 
sterol in the presence of abafungin. Abafungin inhibited 
incorporation of radioactivity into sterol at 0.01   g/ml or 
higher ( table 9 ). The inhibitory effect was noted at much 
lower concentrations than for sinefungin, the S-adeno-
syl- L -methionine antagonist of choice. This result shows 
that abafungin inhibits transmethylation of the sterol 
side chain at low concentrations (0.01–10   g/ml).
Table 8. MFC’s of abafungin at different pH values
Clinical insolates (n) Cumulative percentage of strains killed (99% reduction of 1104 CFU/ml after 
3 days of incubation in Kimmig at 37° C)
2 4 8 16 32 64 pH
C. albicans
C. glabrata
C. tropicalis
(10)
(10)
(10)
10 10
30
30
30
40
100
100 90 100 3.0
C. albicans
C. glabrata
C. tropicalis
(10)
(10)
(10)
 
20
10
20
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50
90
100
100
70 100
4.0
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C. glabrata
C. tropicalis
(10)
(10)
(10)
10 10
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10
60
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60
100
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100
100
 5.0
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C. glabrata
C. tropicalis
(10)
(10)
(10)
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 Fig. 5. Effect of abafungin on the release of potassium from  C. 
albicans TIMM 0144. 
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E = 0.02
 Fig. 8. Difference spectra of abafungin 
with phospholipids. In each case, the 
baseline (bl) and the difference spectrum 
from 190 nm (left side) to 350 nm is shown. 
The concentrations of all phospholipids 
and of abafungin were 10 –4  M , except
for phosphatidylserine + abafungin (each 
5  ! 10 –5  M ). 
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Table 9. Effect of 3h treatment with abafungin and sinefungin on 
sterol composition of  C. albicans 
Substance Concentration 
g/ml
Incorporation rate 
% of control
Abafungin 0.001
0.01
0.1
1
10
92.5
49.5
<2.8
<0.1
<0.1
Sinefungin 1
10
100
82.4
29.6
7.6
 Discussion 
 Arylguanidines are a new class of antifungals distin-
guished by a broad primary antifungal activity against 
dermatophytes, yeast-like fungi and molds. In contrast 
to conventional antifungals of the azole type, they do 
not bind to cytochrome P 450 . Berg et al.  [33] have shown 
that abafungin is a potent inhibitor of ergosterol biosyn-
thesis in  C. albicans at 0.01–1 mg/l. Unlike conventional 
azoles, abafungin inhibits specifically the transmethyl-
ation of the sterol side chain. The enzyme involved in 
this reaction is the sterol-C-24 methyltransferase ( fig. 9 ). 
Ryder  [34] discussed in an early article the same mode 
of action for the allylamine antimycotic naftifine. In a 
publication 1 year later, he stated that the only target of 
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Nucleus
Cytoplasmic membrane
Ergosterol
Ergostatrienol
Episterol
Fecosterol
Zymosterol
14 Dimethyl-Lanosterol
Lanosterol
Squalene epoxide
Squalene
Acetyl-CoA
Polyenes
Amorolfine
Abafungin
Imidazoles/triazoles
Amorolfine
Allylamines
Thiocarbamates
Amorolfine
Abafungin
SAM dependent 
24 SMT
Flucytosine
Griseofulvin
Flucytosine
Griseofulvin
EchinocandinsCiclopirox olamine
 Fig. 9. Dual mode of action of abafungin 
by inhibition of the ergosterol biosynthesis 
and direct impairment of the cell mem-
brane. SAM = S-adenosyl- L -methionine; 
SMT = sterol-C-24 methyltransferase. 
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the allylamines is the block of squalene epoxidation 
 [26] . 
 A partial growth inhibition of  C. albicans was ob-
served at a drug concentration  6 0.1 mg/l. Fungicidal ef-
fects required 10–30 mg/l of abafungin. In this concen-
tration range, membrane functions were impaired short-
ly after drug addition. In a culture of resting cells, a rapid 
leakage of potassium and ATP was observed similar to 
polyenes. Conductivity increased within 1–5 min after 
drug addition corresponding to extracellular potassium 
and ATP. Simultaneously, the cells degraded ATP to re-
store the membrane functions. About 7 min after abafun-
gin addition, ATP depletion of the cells could be ob-
served. At this time point, all remaining ATP (  60%) 
was accumulated extracellularly. Already after 5 min, the 
number of CFU of the culture was reduced  ! 0.1% pre-
sumably as a consequence of breakdown of the energy 
metabolism. In growing cells of  C. albicans , a short sig-
nificant increase in ATP synthesis was observed above 
control level followed by ATP degradation. Compared to 
resting cells, a comparable loss of viability was reached 
later, at about 30 min, presumably because membrane re-
pair mechanisms were more effective in growing cells. 
This assumption is supported by the fact that ATP leak-
age was markedly reduced in growing cells, indicating 
that abafungin has a membrane-damaging effect analo-
gous to the one found with dodecylguanidine (dodine) 
and sertaconazole, for example  [35] .
 Further investigations were concerned with the ques-
tion of whether the observed membrane-damaging ef-
fects of abafungin are related to a specific interaction 
with membrane components like lipids, and phospho-
lipids in particular. Specific interactions of different 
 compounds can be studied by recording UV difference 
spectra  [36] . Interestingly, a significant spectrum of aba-
fungin was obtained only with the phospholipid phos-
phatidylserine but not with phosphatidylcholine, phos-
phatidylethanolamine, phosphatidylinositol, cardiolipin 
and sterols like ergosterol, cholesterol and sitosterol. This 
indicates a specific interaction of abafungin with this 
membrane component.
 Polyene antifungals like amphotericin B and nystatin 
are known to act by complexing sterols, which results in 
a lethal effect by forming transmembrane pores  [37] . The 
interaction between amphotericin B and ergosterol seems 
to be more favorable for pore formation than that be-
tween amphotericin B and cholesterol  [38] . Cellular com-
ponents like potassium and ATP are found to leak out 
through these pores. Since similar leakage effects can be 
seen in abafungin-treated  C. albicans cultures, it is as-
sumed that a specific interaction of this new compound 
with phosphatidylserine leads to the observed membrane 
leakage and to the loss of the capacity to form colonies. 
The leakage of essential cell components becomes a lethal 
event only if the cells are unable to compensate for the 
membrane damage. Iwatani et al.  [39] have demonstrated 
that the benzylamine butenafine induces the release of 
phosphorylated cellular components from  C. albicans 
cells at 12.5 mg/l. They claim a fungicidal activity at 50 
mg/l. However, according to their own data, using 100 
mg/l butenafine, a reduction in the initial cell count of  C. 
albicans of only one order of magnitude occurred within 
48 h. With abafungin we have demonstrated fungicidal 
activity against growing and resting cells with a reduc-
tion in the initial cell count of at least two or three orders 
of magnitude within  ! 1 h at the concentration which in-
duces leakage of cellular components. Abafungin is a 
protonized alkaline agent which preferably binds to poly-
mers like acid proteins and agaropectin, a polymer found 
in agar. This binding leads to a reduced concentration of 
free agent and as a consequence to reduced drug avail-
ability.
 In polymer-free media, the activity of abafungin is 
mainly limited by its solubility. At neutral pH, about 
1 mg/l can be dissolved. At pH 5.0, the solubility reaches 
about 10 mg/l. All fungal isolates tested to date ( 1 300) 
were sensitive to abafungin at this slightly acidic pH. Us-
ing Kimmig’s medium it was demonstrated that only 10% 
of the clinical yeast isolates were sensitive to the drug at 
pH 6, while all isolates responded at pH 5.
 It has long been known that some azoles can exert fun-
gicidal activity at high concentrations by the induction of 
direct membrane damage  [40] . In its broad antifungal ac-
tivity against metabolizing and resting fungi, abafungin 
is apparently superior to the other antifungals tested. 
When tested against resting dermatophytes, it is even 
more active than terbinafine in this respect.
 The experiments described above indicate that aba-
fungin has at least two mechanisms of action in  Candida 
cells: At concentrations of 10 –7  M , it causes a dose-depen-
dent specific inhibition of ergosterol biosynthesis. In the 
range of 10–40   g/ml (10 –4  M ), the agent induces release 
of potassium and ATP from yeast cells. The impairment 
of the cell membrane correlates with loss of viability. In 
the same concentration range where fungicidal activity 
was observed (5  ! 10 –5 to 10 –4  M ), a significant interac-
tion of abafungin with the phospholipid phosphatidyl-
serine but not with other phospholipids or sterols could 
be recorded.
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 Concerning direct impairment of the cell membrane, 
polyene antimycotics like amphotericin B and nystatin 
are known to act by binding to sterol, especially to ergos-
terol, which then leads to their lethal effect by forming 
transmembrane pores  [38] . Cellular components like po-
tassium ions and ATP then leak out through these pores. 
Moreover, some azoles exert fungicidal activity at high 
concentrations by the induction of direct impairment of 
the cell membrane, too  [39–41] .
 In order to assess the clinical potential of abafungin 
further, in vitro data must be confirmed by data on in 
vivo antifungal activities in experimentally infected ani-
mals, and on the pharmacokinetics of the drug in ani-
mals and humans.
 Conclusion 
 The above-described experiments and their results re-
garding abafungin, with relatively high and broad-spec-
trum antifungal activity, indicate that it might be a prom-
ising and useful additional agent in the therapeutic arma-
mentarium for the topical treatment of fungal skin 
disease.
 Acknowledgment 
 We thank the late Prof. Dr. K. Schaller for various, most valu-
able contributions to this paper. The authors are grateful to Dr. A. 
Polak for critical review of the manuscript. 
 References 
 1 Vanden Bossche H, Dromer F, Improvisi I, 
Lozano-Chiu M, Rex JH, Sanglard D: Anti-
fungal drug resistance in pathogenic fungi. 
Med Mycol 1998; 36(suppl 1):119–128. 
 2 Shao PL, Huang LM, Hsueh PR: Recent ad-
vances and challenges in the treatment of in-
vasive fungal infections. Int J Antimicrob 
Agents 2007; 30: 487–495. 
 3 Anderson JB: Evolution of antifungal-drug 
resistance: mechanisms and pathogen fit-
ness. Nat Rev Microbiol 2005; 3: 547–556. 
 4 de Pauw BE, Meunier F: The challenge of in-
vasive fungal infection. Chemotherapy 1999; 
 45(suppl 1):1–14. 
 5 Zhang AY, Camp WL, Elewski BE: Advances 
in topical and systemic antifungals. Derma-
tol Clin 2007; 25: 165–183, vi. 
 6 Gupta AK, Tomas E: New antifungal agents. 
Dermatol Clin 2003; 21: 565–576. 
 7 Ghannoum MA, Rice LB: Antifungal agents: 
mode of action, mechanisms of resistance, 
and correlation of these mechanisms with 
bacterial resistance. Clin Microbiol Rev 
1999; 12: 501–517. 
 8 Bastert J, Schaller M, Korting HC, Evans EG: 
Current and future approaches to antimy-
cotic treatment in the era of resistant fungi 
and immunocompromised hosts. Int J Anti-
microb Agents 2001; 17: 81–91. 
 9 Francois IE, Aerts AM, Cammue BP, Thevis-
sen K: Currently used antimycotics: spec-
trum, mode of action and resistance occur-
rence. Curr Drug Targets 2005; 6: 895–907. 
 10 Polak A: Mode of action of morpholine de-
rivatives. Ann NY Acad Sci 1988; 544: 221–
228. 
 11 Bohme A, Karthaus M: Systemic fungal in-
fections in patients with hematologic malig-
nancies: indications and limitations of the 
antifungal armamentarium. Chemotherapy 
1999; 45: 315–324. 
 12 Lupetti A, Danesi R, Campa M, Del Tacca M, 
Kelly S: Molecular basis of resistance to azole 
antifungals. Trends Mol Med 2002; 8: 76–81. 
 13 Gupta AK, Shear NH: Terbinafine: an up-
date. J Am Acad Dermatol 1997; 37: 979–
988. 
 14 Korting HC, Schäfer-Korting M: Is tinea un-
guium still widely incurable? A review three 
decades after the introduction of griseoful-
vin. Arch Dermatol 1992; 128: 243–248. 
 15 Edlind TD, Katiyar SK: The echinocandin 
‘target’ identified by cross-linking is a ho-
molog of Pil1 and Lsp1, sphingolipid-depen-
dent regulators of cell wall integrity signal-
ing. Antimicrob Agents Chemother 2004; 48: 
 4491. 
 16 Aperis G, Mylonakis E: Newer triazole anti-
fungal agents: pharmacology, spectrum, 
clinical efficacy and limitations. Expert 
Opin Investig Drugs 2006; 15: 579–602. 
 17 Shigematsu ML, Uno J, Arai T: Effect of ke-
toconazole on isolated mitochondria from 
 Candida albicans . Antimicrob Agents Che-
mother 1982; 21: 919–924. 
 18 Sheehan DJ, Hitchcock CA, Sibley CM: Cur-
rent and emerging azole antifungal agents. 
Clin Microbiol Rev 1999; 12: 40–79. 
 19 Leem SH, Park JE, Kim IS, Chae JY, Sugino 
A, Sunwoo Y: The possible mechanism of ac-
tion of ciclopirox olamine in the yeast  Sac-
charomyces cerevisiae . Mol Cells 2003; 15: 
 55–61. 
 20 Niewerth M, Kunze D, Seibold M, Schaller 
M, Korting HC, Hube B: Ciclopirox olamine 
treatment affects the expression pattern of 
 Candida albicans genes encoding virulence 
factors, iron metabolism proteins, and drug 
resistance factors. Antimicrob Agents Che-
mother 2003; 47: 1805–1817. 
 21 Sigle HC, Thewes S, Niewerth M, Korting 
HC, Schäfer-Korting M, Hube B: Oxygen ac-
cessibility and iron levels are critical factors 
for the antifungal action of ciclopirox against 
 Candida albicans . J Antimicrob Chemother 
2005; 55: 663–673. 
 22 Polak A: Preclinical data and mode of action 
of amorolfine. Dermatology 1992; 184(suppl 
1):3–7. 
 23 Haria M, Bryson HM: Amorolfine. A review 
of its pharmacological properties and thera-
peutic potential in the treatment of onycho-
mycosis and other superficial fungal infec-
tions. Drugs 1995; 49: 103–120. 
 24 Urbina JA, Cohen BE, Perozo E, Cornivelli L: 
Spin-labeled amphotericin B: synthesis, 
characterization, biological and spectro-
scopic properties. Biochim Biophys Acta 
1987; 897: 467–473. 
 25 Polak A, Scholer HJ: Fungistatic activity, up-
take and incorporation of 5-fluorocytosine 
in  Candida albicans , as influenced by pyrim-
idines and purines. II. Studies on distribu-
tion and incorporation. Pathol Microbiol 
(Basel) 1973; 39: 334–337. 
 26 Ryder NS, Frank I, Dupont MC: Ergosterol 
biosynthesis inhibition by the thiocarba-
mate antifungal agents tolnaftate and tolci-
clate. Antimicrob Agents Chemother 1986; 
 29: 858–860. 
 27 Kanafani ZA, Perfect JR: Antimicrobial re-
sistance: resistance to antifungal agents: 
mechanisms and clinical impact. Clin Infect 
Dis 2008; 46: 120–128. 
 28 White TC, Marr KA, Bowden RA: Clinical, 
cellular, and molecular factors that contrib-
ute to antifungal drug resistance. Clin Mi-
crobiol Rev 1998; 11: 382–402. 
 29 Barker KS, Rogers PD: Recent insights into 
the mechanisms of antifungal resistance. 
Curr Infect Dis Rep 2006; 8: 449–456. 
 Abafungin: The New Arylguanidine  Chemotherapy 2008;54:245–259 259
 30 Lundin A, Richardsson A, Thore A: Contin-
uous monitoring of ATP-converting reac-
tions by purified firefly luciferase. Anal Bio-
chem 1976; 75: 611–620. 
 31 Epand RM, Jones AJ, Sayer B: Molecular in-
teractions in the model lipoprotein complex 
formed between glucagon and dimyristoyl-
glycerophosphocholine. Biochemistry 1977; 
 16: 4360–4368. 
 32 Schaller K, Itayama H, Tiemann R, Uchida 
K, Yamaguchi H: XII. Congress of the Inter-
national Society for Human and Animal My-
cology (ISHAM). Adelaide, South Australia, 
1994, P7.3. 
 33 Berg D, Ytayama H, Schaller K, Tiemann R, 
Uchida K, Yamaguchi H, Zywitz A: XII. 
Congress of the International Society for 
Human and Animal Mycology (ISHAM). 
Adelaide, South Australia, 1994, PO2.52, 
D97. 
 34 Ryder NS: Effect of allylamine antimycotic 
agents on fungal sterol biosynthesis mea-
sured by sterol side-chain methylation. J Gen 
Microbiol 1985; 131: 1595–1602. 
 35 Agut J, Palacin C, Salgado J, Casas E, Sacris-
tan A, Ortiz JA: Direct membrane-damag-
ing effect of sertaconazole on Candida albi-
cans as a mechanism of its fungicidal activ-
ity. Arzneimittelforschung 1992;42:721–724. 
 36 Bell JE, Hall C: UV and visible absorbance 
spectroscopy; in Ellis JE (ed): Spectroscopy 
in Biochemistry. (Boca Raton, CRC Press, 
1981. 
 37 Mishra P, Bolard J, Prasad R: Emerging role 
of lipids of  Candida albicans , a pathogenic 
dimorphic yeast. Biochim Biophys Acta 
1992; 1127: 1–14. 
 38 Ramos H, Attias de Murciano A, Cohen BE, 
Bolard J: The polyene antibiotic amphoteri-
cin B acts as a Ca 2+ ionophore in sterol-con-
taining liposomes. Biochim Biophys Acta 
1989; 982: 303–306. 
 39 Iwatani W, Arika T, Yamaguchi H: Two 
mechanisms of butenafine action in  Candi-
da albicans . Antimicrob Agents Chemother 
1993; 37: 785–788. 
 40 Sud IJ, Feingold DS: Heterogeneity of action 
of mechanisms among antimycotic imidaz-
oles. Antimicrob Agents Chemother 1981; 
 20: 71–74. 
 41 Ansehn S, Nilsson L: Direct membrane-
damaging effect of ketoconazole and tiocon-
azole on  Candida albicans demonstrated by 
bioluminescent assay of ATP. Antimicrob 
Agents Chemother 1984; 26: 22–25. 
